This company's value is the DEP technology and the vast potential applications (e.g. COVID nasal spray, DEP remdesivir, etc.) Everything else is secondary in my opinion. I'll acknowledge the oversimplification of this assumption, but if SPL was a potential TO target, I think that's what other companies would be interested in mostly.
I checked my account as I arrived home this afternoon to see my trades go through. Cost average was up (unfortunately?!?), but in the end I've tripled my holdings.
GLTA
Problem is its not been used at all in Australia on covid-19 patients., page-15
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
